Skip to main content
. Author manuscript; available in PMC: 2022 May 7.
Published in final edited form as: J Cyst Fibros. 2019 Aug 23;19(2):284–291. doi: 10.1016/j.jcf.2019.08.001

Figure 1. CLEAR-108 study design.

Figure 1.

Patients visited the study site on days 1, 14, 28, 57, 84, 113, 140, and 168; between study visits, patients were followed by telephone contact (days 7, 21, 42, 63, 70, 77, 98, 119, 126, 133, and 154).

ALIS, amikacin liposome inhalation suspension; CF, cystic fibrosis; CFU, colony-forming units; FEV1, forced expiratory volume in 1 second; HRQoL, health-related quality of life; PFT, pulmonary function testing; PRO, patient-reported outcome; TIS, tobramycin inhalation solution.